DiagnaMed Holdings Corp. · CSE:DMED

DiagnaMed — Investor Presentation (November 2024)

20 slides from DiagnaMed's investor presentation, November 2024

  1. Slide 1: DiagnaMed Holdings Corp. Corporate Presentation

    DiagnaMed Holdings Corp. Corporate Presentation NOVEMBER 2024 CSE: DMED | OTCQB: DGNMF

  2. Slide 2: Summary

    Summary Unlocking the potential of hydrogen for industrial and medical uses EIREX - Modular technology producing hydrogen from water HydroPharm - Oral molecular hydrogen product BRAIN AGE® AI - Brain Health Platform Growing commercial and clinical partnerships Multiple value-creating milestones in 2

  3. Slide 3: Hydrogen Opportunities

    Hydrogen Opportunities Industrial Medical Global hydrogen generation market est USD 170 billion (2023) and expected +1 Billion +1 Billon CAGR of 9.3% from 2024 to 2030 Mental Health Neurodegenerative DiagnaMed CSE: DMED | OTCQB: DGNMF

  4. Slide 4: EIREX Water to Hydrogen Technology

    EIREX Water to Hydrogen Technology DiagnaMed CSE: DMED | OTCQB: DGNMF

  5. Slide 5: EIREX

    EIREX Collaboration with EIREX in developing a novel modular carbon-free technology that extracts hydrogen from water Solving the problems faced by producing hydrogen via electrolysis Scalable solution will offer on-site hydrogen EIREX’s approach uses the unique production in various sizes, from 50

  6. Slide 6: EIREX Key Benefits

    EIREX Key Benefits Low Cost: Produces hydrogen at less than 1.4 kWh per kg, significantly reducing costs. On-Demand: Minimizes hydrogen storage requirements. On-Site Production: Eliminates the need for extensive distribution infrastructure. Self-Powered: Operates without reliance on external grid en

  7. Slide 7: Unlocking the medical potential of Hydrogen

    Unlocking the medical potential of Hydrogen DiagnaMed CSE: DMED | OTCQB: DGNMF

  8. Slide 8: Molecular Hydrogen

    Molecular Hydrogen Molecular hydrogen therapy is a rapidly growing field and poised for clinical adoption Over 2,000 scientific publications on potential therapeutic effects in over 100 human studies Clinically demonstrated to provide antioxidant, anti- inflammatory and neuroprotective effects Diagn

  9. Slide 9: Potential Medical Uses of Hydrogen

    Potential Medical Uses of Hydrogen Our Current Focus Brain Dementia Parkinson’s disease Depression Alzheimer’s disease TBI/Concussions Stroke Stroke Aging Ischemia/reperfusion injuries Inflammation Metabolic Syndrome Side effects by cancer drugs Organ Transplants Sepsis Diabetes Radiotherapy Post-ca

  10. Slide 10: Clinical Validation

    Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF

  11. Slide 11: Limitations of Molecular Hydrogen

    Limitations of Molecular Hydrogen Clinical use is limited primarily due to its: Low hydrogen content Rapid evaporating action in water Lower effective concentration and poor stability Hydrogen inhalation and hydrogen-rich water machines are: Expensive, bulky and complex to use Challenging to determi

  12. Slide 12: Our Solution

    Our Solution HydroPharm™ - novel ‘patent-pending’ oral molecular hydrogen tablet tailored for mental health and neurological disorders Offering different doses, durations, and methods of administration HydroPharm™ Hydrogen producing oral tablets License technology that enable natural hydrogen to mee

  13. Slide 13: Utilizing AI for Brain Health

    Utilizing AI for Brain Health DiagnaMed CSE: DMED | OTCQB: DGNMF

  14. Slide 14: BRAIN AGE AI Estimating BRAIN AGE

    B R A I N A G E A I ® Estimating BR AIN AGE® Providing Brain Health Risk Score Monitoring Overall Brain Health DiagnaMed CSE: DMED | OTCQB: DGNMF

  15. Slide 15: Clinical Validation

    Clinical Validation DiagnaMed CSE: DMED | OTCQB: DGNMF

  16. Slide 16: 2025 Growth Plan

    2025 Growth Plan BR A IN AGE® Commercializing HydroPharm™ & BR AIN AGE® AI Molecular Hydrogen Products Unlock new uses of HydroPharm™ & BR AIN AGE® AI Clinical therapeutic and diagnostic tools for screening, monitoring and treating mental health, neurological and brain injuries Establish HydroPharm™

  17. Slide 17: Relationships

    Relationships DiagnaMed CSE: DMED | OTCQB: DGNMF

  18. Slide 18: Team

    Team Management Research Fabio Chianelli Dr. John Kounios, PhD Founder, Chairman, and CEO Principal Researcher - Brain Age Founder, CEO - PharmaTher Applied Cognitive & Brain Sciences Professor, Founder, President - Revive Thera Drexel University Jing Peng, CPA Dr. James E Galvin, M.D., M.P.H. Chief

  19. Slide 19: Financial Snapshot

    Financial Snapshot 80,052,640 2,000,000 Common Shares outstanding Stock Options 37,382,226 Common Shares are subject to escrow 1/10th released at: November 8, 2023, 2024, 2025 ~ 21% May 8, 2024, 2025, 2026 2/10th released at: Insider Ownership November 8, 2026

  20. Slide 20: Thank You

    THANK YOU DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 t. 416-800-2684 e. info@diagnamed.com DiagnaMed CSE: DMED | OTCQB: DGNMF

DiagnaMed Holdings — Investor Presentation (November 2024) on 6ix